Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56dimCD16bright natural killer cells during kidney allograft antibody–mediated rejection showing a new link between adaptive and innate humoral allo-immunity

Kidney International(2023)10.1016/j.kint.2023.04.024Source: DataRank Database

Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56dimCD16bright natural killer cells during kidney allograft antibody–mediated rejection showing a new link between adaptive and innate humoral allo-immunity is a research paper published in Kidney International (2023). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 2.01)OA: greenTopics (29)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Camila Macedo ORCID,Jason Ossart,Kevin Louis ORCID,Xinyan Gu ORCID,Bala Ramaswami ORCID

Live enrichment

PubMed:37220805 PMC:PMC10524858 OpenAlex:https://openalex.org/W4377194417

NIAID NIH HHS

Grant: R01 AI130010

FWCI

2.01

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10524858/pdf/nihms-1904192.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0085253823003447?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0085253823003447?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10524858

Fields of Study

Immune Cell Function and InteractionCytomegalovirus and herpesvirus researchT-cell and B-cell Immunology

MeSH Terms

Interleukin-21AntibodiesCross-Sectional StudiesGraft RejectionKidneyKiller Cells, NaturalKidney TransplantationAllografts

Keywords

ImmunologyInnate immune systemAcquired immune systemHumoral immunityImmunityAntibodyInterleukin 15Immune systemBiologyMedicineInterleukinCytokineCytotoxicityNatural killer cellKidney transplantationIl-21AlloantibodyAntibody-mediated Rejection

Sustainable Development Goals

SDG 0: Good health and well-being

Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56dimCD16bright natural killer cells during kidney allograft antibody–mediated rejection showing a new link between adaptive and innate humoral allo-immunity

FAIR Checklist

Authors (11)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)